Status:
WITHDRAWN
Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to examine the effect of rifampin on the drug levels in blood and safety of BMS-986235, when taken by healthy participants.
Eligibility Criteria
Inclusion
- For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
- Healthy participants, as determined by no clinically significant deviation from normal in physical examination, ECGs, and clinical laboratory determinations; no significant findings in medical history.
- Body mass index of 18.0 kg/m2 to 30.0 kg/m2, inclusive, at screening
- Males must agree to follow specific methods of contraception, if applicable
Exclusion
- Women of childbearing potential (WOCBP)
- Known previous exposure to BMS-986235
- History of any significant drug allergy
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
March 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 16 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04301310
Start Date
March 9 2020
End Date
March 16 2020
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Salt Lake City, Utah, United States, 84124